JP2024510606A5 - - Google Patents

Info

Publication number
JP2024510606A5
JP2024510606A5 JP2023555666A JP2023555666A JP2024510606A5 JP 2024510606 A5 JP2024510606 A5 JP 2024510606A5 JP 2023555666 A JP2023555666 A JP 2023555666A JP 2023555666 A JP2023555666 A JP 2023555666A JP 2024510606 A5 JP2024510606 A5 JP 2024510606A5
Authority
JP
Japan
Prior art keywords
diazabicyclo
chloro
methoxy
octan
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510606A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020239 external-priority patent/WO2022192794A1/en
Publication of JP2024510606A publication Critical patent/JP2024510606A/ja
Publication of JP2024510606A5 publication Critical patent/JP2024510606A5/ja
Pending legal-status Critical Current

Links

JP2023555666A 2021-03-12 2022-03-14 Kras g12d阻害剤 Pending JP2024510606A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163160431P 2021-03-12 2021-03-12
US63/160,431 2021-03-12
US202163173021P 2021-04-09 2021-04-09
US63/173,021 2021-04-09
US202163220386P 2021-07-09 2021-07-09
US63/220,386 2021-07-09
US202163236497P 2021-08-24 2021-08-24
US63/236,497 2021-08-24
PCT/US2022/020239 WO2022192794A1 (en) 2021-03-12 2022-03-14 Kras g12d inhibitors

Publications (2)

Publication Number Publication Date
JP2024510606A JP2024510606A (ja) 2024-03-08
JP2024510606A5 true JP2024510606A5 (cg-RX-API-DMAC7.html) 2025-03-24

Family

ID=81213567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555666A Pending JP2024510606A (ja) 2021-03-12 2022-03-14 Kras g12d阻害剤

Country Status (11)

Country Link
US (1) US20240317769A1 (cg-RX-API-DMAC7.html)
EP (1) EP4305038B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510606A (cg-RX-API-DMAC7.html)
KR (1) KR20230169967A (cg-RX-API-DMAC7.html)
AU (1) AU2022232523A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017763A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210053A1 (cg-RX-API-DMAC7.html)
ES (1) ES3013592T3 (cg-RX-API-DMAC7.html)
IL (1) IL305568A (cg-RX-API-DMAC7.html)
MX (1) MX2023010430A (cg-RX-API-DMAC7.html)
WO (1) WO2022192794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
CN116323624B (zh) * 2020-09-30 2026-07-10 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
CN115181106B (zh) * 2021-04-07 2024-04-05 药雅科技(上海)有限公司 喹唑啉类krasg12d突变蛋白抑制剂的制备及其应用
WO2022232331A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
CA3221811A1 (en) * 2021-06-30 2023-01-05 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of kras g12d mutant
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
JP7629580B1 (ja) * 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN118344386A (zh) * 2023-01-13 2024-07-16 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
KR20250075709A (ko) * 2022-09-30 2025-05-28 트라스베다 리미티드 항-kras 돌연변이 종양 활성을 갖는 화합물
EP4631942A1 (en) 2022-10-21 2025-10-15 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Pan-kras degrading agent, and preparation method therefor and use thereof
CN117917416A (zh) 2022-10-21 2024-04-23 上海领泰生物医药科技有限公司 Kras g12d降解剂及其制备方法和应用
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用
CN120166992A (zh) * 2022-10-31 2025-06-17 上海皓元医药股份有限公司 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121419981A (zh) * 2023-03-03 2026-01-27 前沿药品公司 用于制备吡咯里西啶化合物的方法
CN117903192A (zh) * 2023-03-12 2024-04-19 上海相辉医药科技有限公司 一种3-甲氧基异喹啉化合物中间体的制备方法
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024215862A2 (en) * 2023-04-12 2024-10-17 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024227091A1 (en) * 2023-04-26 2024-10-31 Ranok Therapeutics (Hangzhou) Co. Ltd. Diazabicyclooctane inhibitors of kras (g12d) and uses
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024230707A1 (zh) * 2023-05-07 2024-11-14 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR102738924B1 (ko) * 2023-12-26 2024-12-06 주식회사 베노바이오 Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN110869358A (zh) * 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022002102A1 (en) * 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
MX2023008463A (es) * 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).

Similar Documents

Publication Publication Date Title
JP2024510207A5 (cg-RX-API-DMAC7.html)
JP7313354B2 (ja) Tlr阻害剤として有用なアミド置換されたインドール化合物
CN105294683B (zh) Cdk类小分子抑制剂的化合物及其用途
KR20230167386A (ko) 옥사제핀 화합물 및 암 치료에서의 이의 사용
JP2025533831A (ja) Kras g12c変異タンパク質のテザー型複素環式阻害剤及びその使用
KR20250013185A (ko) 아자-테트라시클릭 옥사제핀 화합물 및 이의 용도
DK2536730T3 (en) Pyrrolopyrimidinforbindelser as CDK4 / 6 inhibitors
JP2024532735A5 (cg-RX-API-DMAC7.html)
JP2024532734A5 (cg-RX-API-DMAC7.html)
JP2022501338A5 (cg-RX-API-DMAC7.html)
WO2025080592A1 (en) Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer
HRP20240293T1 (hr) Derivati kinazolina kao protutumorska sredstva
CN112166110A (zh) Shp2磷酸酶抑制剂及其使用方法
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
CN108366992A (zh) 蛋白水解靶向嵌合体化合物及其制备和应用方法
JP2017531672A5 (cg-RX-API-DMAC7.html)
JP2015524798A5 (cg-RX-API-DMAC7.html)
RU2017117248A (ru) Этил-n-boc-пиперидинил-пиразоло-пиридоны в качестве ингибиторов янус-киназы
PE20191349A1 (es) Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos
HRP20241222T1 (hr) Makrociklički spojevi kao agonisti sting, te postupci i njihova upotreba
JP2018522929A5 (cg-RX-API-DMAC7.html)
KR102912146B1 (ko) 시클로알칸-1,3-디아민 유도체
JP2018523689A (ja) ホスホイノシチド3−キナーゼ阻害剤および第二の抗増殖剤を含む組成物
WO2025194134A1 (en) Linearly substituted oxazepin-5-one kras-g12d inhibitors
EA037401B1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k